← All companies

AVLN

Avalyn Pharma Inc.

AVLN Nasdaq Pharmaceutical Preparations EDGAR ↗

$28.50

-0.81 -2.76%

Key statistics

from XBRL data in SEC filings

Market cap

$1.26B

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$92.3M

Total assets

$136M

Gross margin

—

52-week range

$24.15 – $33.32

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement Jul 1, 2026 8-K Regulation FD disclosure Jun 17, 2026 10-Q Quarter ended 2026-03-31 Jun 3, 2026 8-K Results of operations (earnings release) Jun 3, 2026 8-K Amended charter or bylaws May 1, 2026

Other filings

SCHEDULE 13D May 8, 2026 SCHEDULE 13D May 8, 2026 SCHEDULE 13G May 7, 2026 4 May 5, 2026 SCHEDULE 13G May 5, 2026 4 May 5, 2026 4 May 4, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 4 May 1, 2026 S-8 Apr 30, 2026 424B4 Apr 30, 2026 EFFECT Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026 3 Apr 29, 2026